ArticleMedical oncology (Northwood, London, England)2026
Nutritional inflammatory hematological risk index predicts clinical outcomes in patients with advanced NSCLC receiving immunotherapy.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In real-world clinical settings, patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) display significant heterogeneity, highlighting the need to identify key prognostic biomarkers and clinical factors. This retrospective study included 340 advanced NSCLC patients treated with ICIs. Cox regression analyses identified factors associated with progression-free survival (PFS). A Nutritional Inflammatory Hematological Risk Index (NIHRI) was constructed using these factors, and a prognostic nomogram was developed. Performance was assessed using the C-index, calibration plots, and decision curve analysis (DCA), with internal validation via bootstrapping. Hemoglobin and the albumin-to-alkaline phosphatase ratio (AAPR) were independent prognostic factors. The NIHRI, combining dichotomized hemoglobin (< 120 g/L vs. ≥120 g/L) and AAPR (< 0.56 vs. ≥0.56), stratified patients into low- (0 points), intermediate- (1 point), and high-risk (2 points) groups, with significantly different PFS (P<0.001). The nomogram, incorporating NIHRI, tumor stage, PD-L1, and ECOG-PS, demonstrated a C-index of 0.70 (optimism-corrected: 0.69) and predictive accuracy for 1-, 2-, and 3-year PFS (AUCs: 0.81, 0.85, and 0.88, respectively). DCA confirmed its acceptable clinical net benefit. We developed and validated a novel prognostic tool, the NIHRI, based on a combination of hemoglobin and AAPR. This integrated nomogram provides a non-invasive and clinically accessible quantitative method for predicting prognosis in patients with NSCLC undergoing immunotherapy, thereby aiding in personalized clinical decision-making.
Indexed as
Identifiers
42848307What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.